Analysis for Novo Nordisk (Class B)
Analysis summary
Novo Nordisk (Class B) (NOVO-B.CO) currently has a total score of 23 points, placing it in the weak range. The score is made up of Performance (29), Stability (15) and Trend (18). All three sub-scores are currently below average.
Performance scores 29 points (weak). Least weak metric: 5Y return at 40.6 %. Main drag: 1Y return at -47.1 %.
Stability scores 15 points (very weak). Least weak metric: CAGR/drawdown ratio at 0.07. Main drag: max drawdown (1Y) at -69.1 %. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 18 points (very weak). Trend signals are mostly negative right now. Least weak metric: trend strength at 0.10. Main drag: 12M momentum at -35.5 %.
Overall, the score is shaped most by Performance; Stability trails and dampens the total. On a metric level, 5Y return stands out, while 1Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Performance
Stability
FAQ
- What investor type does Novo Nordisk (Class B) fit best in FoxScore?
- Novo Nordisk (Class B) shows a mixed profile: performance is strongest, but stability lags noticeably. Use the sub-scores as a radar, then decide based on the metrics whether the risk/return profile fits you.
- How meaningful is the available history for Novo Nordisk (Class B)?
- Novo Nordisk (Class B) currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.